EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?

Giuseppe Boriani, Luigi Gerra, Davide A Mei, Niccolo' Bonini, Marco Vitolo, Marco Proietti, Jacopo F Imberti

European Journal of Internal Medicine · 2024-05 · 123 · 37-41

DOI: 10.1016/j.ejim.2024.01.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-05. Verfasst von Giuseppe Boriani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Mo…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Defibrillators, Implantable, Stroke. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atrial fibrillation (AF) may be asymptomatic and the extensive monitoring capabilities of cardiac implantable electronic devices (CIEDs) revealed asymptomatic atrial tachi-arrhythmias of short duration (minutes-hours) occurring in patients with no prior history of AF and without AF detection at a conventional surface ECG. Both the terms "AHRE" (Atrial High-Rate Episodes) and subclinical AF were used in a series of prior studies, that evidenced the association with an increased risk of stroke. Two randomized controlled studies were planned in order to assess the risk-benefit profile of anticoagulation in patients with AHRE/subclinical AF: the NOAH and ARTESiA trials. The results of these two trials (6548 patients enrolled, overall) show that the risk of stroke/systemic embolism associated with AHRE/subclinical AF is in the range of 1-1.2 % per patient-year, but with an important proportion of severe/fatal strokes occurring in non-anticoagulated patients. The apparent discordance between ARTESiA and NOAH results may be approached by considering the related study-level meta-analysis, which highlights a consistent reduction of ischemic stroke with oral anticoagulants vs. aspirin/placebo (relative risk [RR] 0.68, 95 % CI 0.50-0.92). Oral anticoagulation was found to increase major bleeding (RR 1.62, 95 % CI 1.05-2.5), but no difference was found in fatal bleeding (RR 0.79, 95 % CI 0.37-1.69). Additionally, no difference was found in cardiovascular death or all-cause mortality. Taking into account these results, clinical decision-making for patients with AHRE/subclinical AF at risk of stroke, according to CHA2DS2-VASc, can now be evidence-based, considering the benefits and related risks of oral anticoagulants, to be shared with appropriately informed patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsDefibrillators, ImplantableStrokeRandomized Controlled Trials as TopicHumansPacemaker, ArtificialClinical Decision-MakingRisk Assessment

Stichwörter der Autor:innen

AnticoagulantsAtrial cardiomyopathyAtrial fibrillationDefibrillatorPacemakerStroke

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy. Electronic address: giuseppe.boriani@unimore.it.
  • Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
  • Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; Clinical and Experimental Medicine PhD Program, Universit…
  • Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Division of Subacute Care IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.

Förderung

  • European Commission
  • Horizon 2020

Zitieren

APA

Boriani, G., Gerra, L., Mei, D. A., Bonini, N., Vitolo, M., Proietti, M., & Imberti, J. F. (2024). Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?. European Journal of Internal Medicine, 123, 37-41. https://doi.org/10.1016/j.ejim.2024.01.002

Vancouver

Boriani G, Gerra L, Mei DA, Bonini N, Vitolo M, Proietti M, et al. Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?. European Journal of Internal Medicine. 2024;123:37-41. doi:10.1016/j.ejim.2024.01.002

BibTeX
@article{Boriani2024,
  author = {Boriani, Giuseppe and Gerra, Luigi and Mei, Davide A and Bonini, Niccolo' and Vitolo, Marco and Proietti, Marco and Imberti, Jacopo F},
  title = {Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  volume = {123},
  pages = {37--41},
  doi = {10.1016/j.ejim.2024.01.002}
}
Kostenlos starten →